Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus INDERIDE LA 120 50.
BETAGAN vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination